France has decided to make its own vaccine after some time administering other Covid vaccines including AstraZeneca – developed in the UK
The French people have already begun to quiz the efficacy of AstraZeneca and other vaccines available preferring to wait for the new coronavirus vaccine that is being produced by a French pharmaceutical company. It is believed that the new French vaccine, Valneva, will have an efficacy of over 80 percent.
In a statement, Franck Grimaud, the general manager of Franco-Austrian laboratory Valneva, said: “On the basis (…) of the phase I and II trials, we hope to have a vaccine which is effective in more than 80 percent of cases. It will have to be demonstrated in the phase III trial.”
According to the general manager, Valneva uses a deactivated virus vaccine, a more old-world technology than RNA, which is used specifically for influenza vaccines.
Franck Grimaud added: “There are many parameters to consider in a vaccine: efficacy, harmlessness, period of protection, duration between the first two doses, and the need for a booster…” continued Franck Grimaud.
However, the longer the people wait the lower are the chances of curbing the spread of the coronavirus in France.
“I hear some people say that they prefer to wait for the vaccine from Sanofi to be vaccinated. I thank those who trust Sanofi but, our vaccine will not arrive for several months,” the boss of another French pharmaceutical company called Sanofi said.
“Waiting only increases the risk and prolongs the circulation of the virus. The vaccines authorized by the Health Authorities are safe and effective.”
The post New French Vaccine Development Lowers Uptake Of Other Vaccines appeared first on SurgeZirc UK.